Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;22(4):e202402248.
doi: 10.1002/cbdv.202402248. Epub 2025 Jan 3.

Research Progress on Natural Products Alleviating Liver Inflammation and Fibrosis via NF-κB Pathway

Affiliations
Review

Research Progress on Natural Products Alleviating Liver Inflammation and Fibrosis via NF-κB Pathway

Xiaoying Li et al. Chem Biodivers. 2025 Apr.

Abstract

Liver fibrosis is a key pathological process in chronic liver diseases, regulated by various cytokines and signaling pathways. Among these, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway plays a significant role in the initiation and progression of liver fibrosis. Recently, natural products have garnered attention as potential anti-fibrotic agents. This review highlights recent studies on how natural products, including flavonoids, terpenoids, polysaccharides, phenols, alkaloids, quinones, phenylpropanoids, steroids, and nitrogen compounds, mitigate liver fibrosis by modulating the NF-κB signaling pathway. Specifically, it examines how these natural products influence NF-κB activation, nuclear translocation, and downstream signaling, thereby inhibiting inflammatory responses, reducing apoptosis, and regulating hepatic stellate cell (HSC) activity, ultimately achieving therapeutic effects against liver fibrosis. A deeper understanding of the mechanisms by which natural products regulate the NF-κB signaling pathway can provide crucial theoretical foundations and valuable insights for the development of novel anti-fibrotic drugs.

Keywords: liver fibrosis; natural products; nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathway.

PubMed Disclaimer

Similar articles

Cited by

References

    1. S. L. Friedman and M. Pinzani, “Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future,” Hepatology 75, no. 2 (2022): 473–488.
    1. S. Seen, “Chronic Liver Disease and Oxidative Stress—A Narrative Review,” Expert Review of Gastroenterology & Hepatology 15, no. 9 (2021): 1021–1035.
    1. T. Luangmonkong, S. Suriguga, H. A. M. Mutsaers, G. M. M. Groothuis, P. Olinga, and M. Boersema, “Targeting Oxidative Stress for the Treatment of Liver Fibrosis,” Reviews of Physiology, Biochemistry and Pharmacology 175 (2018): 71–102.
    1. D. Ezhilarasan, “Oxidative Stress is Bane in Chronic Liver Diseases: Clinical and Experimental Perspective,” Arab Journal of Gastroenterology 19, no. 2 (2018): 56–64.
    1. L. Hammerich and F. Tacke, “Hepatic Inflammatory Responses in Liver Fibrosis,” Nature Reviews Gastroenterology & Hepatology 20, no. 10 (2023): 633–646.

MeSH terms

LinkOut - more resources